
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.












Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Mark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.

Biopsy-based cell cycle progression gene expression testing can aid in the stratification of patients with localized prostate cancer based on disease aggressiveness.


Samir Taneja, MD, professor of Urology and Radiology and director of the Division of Urologic Oncology at NYU Langone Medical Center.

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

For some insight on this discussion, OncLive sat down with prostate cancer expert and president-elect of SUO, Leonard G. Gomella, MD.

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.
























































